Inflation Explained: Restaurants balance rising costs with consumer preferences
Economic struggles and too-good-to-be-true value menus go hand in hand.
Announcing the results of the 2026 INFORMS Board of Directors election and the new board for 2027.
INFORMS has named 12 distinguished leaders as the 2026 class of INFORMS Fellows, one of the highest honors in the profession.
Most medical devices do not hit the market through rigorous safety testing but by being deemed similar enough to something already approved—the “predicate” device through a mechanism known as the FDA’s 510(k) pathway. But similar is not a synonym for safe. While the assumption may be that substantial equivalence is a reasonable stand-in for a safety review, a share of devices cleared with this method still get recalled, and the FDA spends valuable time reviewing devices the same way, regardless of how risky it is on paper.
An audio journey of how data and analytics save lives, save money and solve problems.

Jeff Cohen
Chief Strategy Officer
INFORMS
Catonsville, MD
[email protected]
443-757-3565
Explore our resources for multiple topics including:
Economic struggles and too-good-to-be-true value menus go hand in hand.
Billionaire investor Mark Cuban's question to Representative Matt Gaetz, a Florida Republican, on energy costs took off on social media on Saturday.
Both Amazon and the Transportation Security Administration (TSA) are demanding the biometric data of all Americans.
Too many people in the United States are dying of colorectal cancer (CRC). The #2 cancer killer in the United States, it impacts Black Americans disproportionately. Compared to White adults, Black adults aged 50 and above get colon cancer at a rate that’s 23% higher than White adults and have a 31% higher risk of dying from the disease.1 These disparities persist despite progress in screening and treatment and are particularly frustrating because CRC is highly treatable when caught in early stages and even preventable when pre-cancers are identified and removed through screening. These differences in incidence and mortality persist even while we have made progress to make screening more accessible to all. A 2019 NIH study showed that a similar proportion of Black and White Americans are up to date with CRC screening2, a meaningful improvement since 20053. If screening access and uptake are now so similar, why do these disparities persist?
The test for any breakthrough technology is often where you least expect it, but once it “conquers” that application, even more possibilities may emerge.

OR/MS Today is the INFORMS member magazine that shares the latest research and best practices in operations research, analytics and the management sciences.
Access OR/MS Today Magazine
Analytics magazine showcases articles and research reports based on big data, AI, machine learning, data analytics and other new-age technologies.
Access Analytics Magazine